The FDA is restricting compounded GLP-1 ingredients, warning telehealth companies, and involving the Department of Justice. If you're on compounded semaglutide or tirzepatide, here's what you need to do — and what your options are.
If you are currently using a compounded semaglutide or tirzepatide product, talk to your prescribing provider about transitioning to an FDA-approved alternative. Brand-name self-pay prices have dropped significantly in 2026, and enforcement against compounding pharmacies is accelerating. Do not abruptly stop your medication — work with your provider to plan a safe transition.
FDA confirms semaglutide shortage is resolved. National supply from Novo Nordisk meets demand.
Enforcement discretion ends for 503A pharmacies (state-licensed pharmacies compounding semaglutide under individual prescriptions).
Enforcement discretion ends for 503B outsourcing facilities (larger-scale compounders distributing semaglutide without patient-specific prescriptions).
FDA sends "thousands" of warning letters to telehealth companies and pharmacies over misleading advertising of compounded GLP-1 products.
Hims & Hers launches compounded oral semaglutide product — marketed as containing "the same active ingredient as Wegovy."
FDA Commissioner Martin Makary announces intent to "take decisive steps" to restrict GLP-1 APIs for non-FDA-approved compounded drugs. Same day: HHS General Counsel refers Hims & Hers to the Department of Justice.
Hims & Hers withdraws the compounded oral semaglutide product — less than 48 hours after launch.
FDA enforcement action against 30+ telehealth companies. Warning letters state that compounded drugs cannot claim to be generic, equivalent, or produce identical outcomes to FDA-approved products. Roughly 80% of compounded GLP-1 prescriptions now include supplemental ingredients (B vitamins, etc.) to circumvent the "essentially a copy" restriction.
The FDA's position is now explicit: compounded GLP-1 medications "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." With the semaglutide shortage resolved, brand-name Wegovy and Ozempic commercially available, and self-pay prices at historical lows, the agency sees fewer legitimate justifications for compounded versions.
This doesn't mean all compounding is illegal. Patient-specific compounding under Section 503A remains legal when a documented medical need exists — for example, a genuine allergy to an inactive ingredient in the FDA-approved product. But the mass-market compounding model (large-scale production and distribution through telehealth platforms) is the primary enforcement target.
The enforcement isn't just regulatory posturing. The FDA has documented real safety issues with compounded GLP-1 products:
If you're using a compounded GLP-1 product, verify: (1) your pharmacy is state-licensed, (2) the active ingredient is semaglutide base (not a salt form), (3) the product is stored and shipped properly (refrigerated, adequate ice packs), and (4) your provider has a documented medical justification for compounding. If any of these fail, discuss transitioning to an FDA-approved option.
The good news: brand-name GLP-1 prices have dropped close enough to compounded prices that the transition is financially viable for many patients.
Multiple telehealth platforms have transitioned or are transitioning to FDA-approved medication programs. These platforms handle the entire process — consultation, prescription, and delivery — and work exclusively with FDA-approved products and licensed pharmacies.
Streamlined telehealth with both semaglutide and tirzepatide options through compliant pharmacy channels.
Check Eligibility →Transparent pricing across weight loss programs. Licensed providers who can help you transition from compounded to FDA-approved options.
Explore Options →The compounding pathway for GLP-1s is narrowing rapidly. The FDA has signaled it will use "all available compliance and enforcement tools," including seizure and injunction, against entities manufacturing, distributing, or marketing non-FDA-approved compounded GLP-1 products. Several lawsuits (OFA v. FDA) challenging the enforcement have been unsuccessful at the district court level, with appeals pending.
For patients, the practical takeaway: if you're currently on a compounded GLP-1 product, don't wait for your pharmacy to be shut down. Proactively plan your transition. The brand-name alternatives are more affordable than ever, and a smooth transition — ideally coordinated with your provider at equivalent dosing — can avoid any interruption in treatment.
FDA-approved medication programs paired with coaching support. A good option for patients transitioning who want structured support through the switch.
Learn More →